Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized placebo-controlled induction study of oral TAK-279 in moderate to severe active ulcerative colitis
MOH_2025-09-21_014358Phase 2Active, not recruiting
- Sponsor
- Takeda
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zasocitinib in autoimmune colitis (3 arms), sponsored by Takeda. Started Sep 2025; status: active, not recruiting.
02
Drugs
zasocitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2025-09-21_014358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-09-21_014358.